7.1.2. surgical treatment. 7.1.2.1. nephron-sparing surgery versus radical nephrectomy localised rcc 7.1.2.1.1. t1 rcc outcome 1: cancer-specific survivalmost studies comparing oncological outcomes pn rn retrospective include cohorts varied and, overall, limited size . one, prematurely closed, prospective rct including patients organ-confined rccs limited size (< 5 cm) published, showing comparable non-inferiority css pn vs. rn (hr: 2.06 [95% ci: 0.62–6.84]) . outcomes 2 & 3: overall mortality renal functionpartial nephrectomy preserved kidney function better surgery, thereby potentially lowering risk development cardiovascular disorders [270,273-277]. compared radical surgical approach, several retrospective analyses large databases suggested decreased cardiovascular-specific mortality well improved os pn compared rn. however, series held true younger patients and/or patients without significant comorbidity time surgical intervention . analysis u.s. medicare database could demonstrate os benefit patients ≥ 75 years age rn pn compared non-surgical management. conversely, another series addressed question included medicare patients, suggested os benefit older patients (75-80 years) subjected surgery rather non-surgical management. shuch et al., compared patients underwent pn rcc non-cancer healthy control group via retrospective database analysis; showing os benefit cancer cohort . conflicting results may indication unknown statistical confounders hamper retrospective analysis population- based tumour registries. prospectively randomised, prematurely closed, heavily underpowered, trial, pn seems less effective rn terms os intention treat (itt) population (hr: 1.50 [95% ci: 1.03–2.16]). however, targeted rcc population rct, trend favour rn longer significant . taken together, os advantage suggested pn vs. rn remains unresolved issue. patients normal pre-operative renal function decreased gfr due surgical treatment (either rn pn), generally present stable long-term renal function . adverse os patients pre-existing gfr reduction seem result renal function impairment following surgery, rather medical comorbidities causing pre-surgical chronic kidney disease (ckd) . however, particular patients pre-existing ckd, pn treatment choice limit risk development esrd requires haemodialysis. huang et al., found 26% patients newly diagnosed rcc gfr ≤ 60 ml/min, even though baseline serum creatinine levels normal range . outcomes 4 & 5: peri-operative outcomes quality lifein terms intra- peri-operative morbidity/complications associated pn vs. rn, european organisation research treatment cancer (eortc) randomised trial showed pn small, easily resectable, incidentally discovered rcc, presence normal contralateral kidney, performed safely slightly higher complication rates rn . limited number studies available addressing quality life (qol) following pn vs. rn, irrespective surgical approach used (open vs. minimally invasive). quality life ranked higher following pn compared rn, general patients’ health status deteriorated following approaches . view above, since oncological safety (css rfs) pn, far, found non-differing rn outcomes, pn treatment choice t1 rcc since preserves kidney function better long term pn potentially limits incidence cardiovascular disorders development esrd need haemodialysis. irrespective available data, frail patients, treatment decisions individualised, weighing risks benefits pn vs. rn, increased risk peri-operative complications, risk developing worsening ckd post-operatively. 7.1.2.1.2. t2 rcc limited evidence optimal surgical treatment patients larger renal masses (t2). retrospective comparative studies pn vs. rn t2 rcc published . trend lower tumour recurrence- csm reported pn groups. estimated blood loss reported higher pn groups, likelihood post-operative complications . multicentre study compared survival outcomes patients larger (> 7 cm) ccrcc treated pn vs. rn long-term follow- (median 102 months). compared rn group, pn group significantly longer median os (p = 0.014) median css (p = 0.04) . retrospective comparative studies ct1 ct2 rcc patients upstaged pt3a rcc show contradictory results: reports suggest similar oncologic outcomes pn rn , whilst another recent report suggests pn clinical t1 pathologically upstaged pt3a ct1 rcc associated significantly shorter rfs rn . overall, level evidence low. studies including t2 masses high risk selection bias due imbalance pn rn groups regarding patient’s age, comorbidities, tumour size, stage, tumour position. imbalances covariation factors may greater impact patient outcome choice pn rn. panel’s confidence results limited true effects may substantially different. view above, risks benefits pn discussed patients t2 tumours. setting pn considered, technically feasible, patients solitary kidney, bilateral renal tumours ckd sufficient parenchymal volume preserved allow sufficient post-operative renal function. 7.1.2.1.3. t3 rcc meta-analysis nine articles including 1,278 patients pn 2,113 patients rn pt3a rcc showed difference css, os, csm rfs, indicating pn techniques used functional benefits technically feasible . 7.1.2.2. associated procedures 7.1.2.2.1. adrenalectomy one prospective nrs compared outcomes rn with, without, ipsilateral adrenalectomy . multivariable analysis showed upper pole location predictive adrenal involvement, tumour size was. difference os five ten years seen with, without, adrenalectomy. adrenalectomy justified using criteria based radiographic- intra-operative findings. 48 2,065 patients underwent concurrent ipsilateral adrenalectomy 42 48 interventions benign lesions . 7.1.2.2.2. lymph node dissection clinically negative lymph nodes (cn0) indication ln dissection (lnd) together pn rn still controversial . clinical assessment ln status based detection enlargement lns either ct/mri intra- operative palpability enlarged nodes. less 20% suspected metastatic nodes (cn+) positive metastatic disease histopathological examination (pn+) . ct mri unsuitable detecting malignant disease nodes normal shape size . clinically positive lns (cn+) see section 7.2.2. smaller retrospective studies suggested clinical benefit associated less extensive lnd, preferably patients high risk lymphogenic spread. large retrospective study, outcomes rn with, without, lnd, patients high-risk non-mrcc compared using propensity score analysis. study lnd significantly associated reduced risk distant metastases, cancer- specific all-cause mortality. extent lnd associated improved oncologic outcomes . number ln metastases (< / > 4) well intra- extra-capsular extension intra-nodal metastasis correlated patients´ clinical prognosis studies [294,296-298]. better survival outcomes seen patients low number positive lns (< 4) extra-nodal extension. based retrospective surveillance, epidemiology end results (seer) database analysis > 9,000 patients effects extended lnd (elnd) disease-specific survival (dss) patients pathologically- confined negative nodes demonstrated . however, patients pathologically proven lymphogenic spread (pn+), increase 10 number nodes dissected resulted 10% absolute increase dss. addition, larger cohort 1,983 patients, capitanio et al., demonstrated elnd results significant prolongation css patients unfavourable prognostic features (e.g., sarcomatoid differentiation, large tumour size) . morbidity related elnd, retrospective propensity score analysis large single-centre database showed elnd associated increased risk clavien grade > 3 complications. furthermore, lnd associated length hospital stay estimated blood loss . one prospective rct evaluating clinical value lnd combined surgical treatment primary rcc published far. incidence ln involvement 4%, risk lymphatic spread appears low. recognising latter, staging effect attributed lnd . trial included high percentage patients pt2 tumours, increased risk ln metastases. 25% patients pt3 tumours underwent complete lnd ln template used authors clearly stated. optimal extent lnd remains controversial. retrospective studies suggest elnd involve lns surrounding ipsilateral great vessel inter-aortocaval region crus diaphragm common iliac artery. involvement inter-aortocaval lns without regional hilar involvement reported 35-45% cases . least fifteen lns removed . sentinel lnd investigational technique . 7.1.2.2.3. embolisation routine nephrectomy, tumour embolisation benefit . patients unfit surgery, non-resectable disease, embolisation control symptoms, including visible haematuria flank pain . indications revisited sections 7.2 7.3 cross reference summary evidence recommendations below. 7.1.2.2.4. summary evidence recommendations treatment localised rcc summary evidencelethe oncological outcome terms os following pn equals rn patients c/p t1 rcc.1bretrospective studies suggest oncological outcomes similar following pn vs. rn patients larger (≥ 7 cm) rcc. post-operative complication rates higher pn patients.3bipsilateral adrenalectomy rn pn survival advantage absence clinically evident adrenal involvement.3in patients localised disease without radiographic evidence ln metastases, survival advantage lnd conjunction rn demonstrated rcts.2bretrospective studies suggest clinical benefit associated lnd high-risk patients.2bin patients unfit surgery massive haematuria flank pain, embolisation beneficial palliative approach.3 recommendationsstrength ratingoffer surgery achieve cure localised renal cell cancer.strongoffer partial nephrectomy (pn) patients t1 tumours.strongoffer pn patients t2 tumours solitary kidney chronic kidney disease, technically feasible.weakdo perform ipsilateral adrenalectomy clinical evidence invasion adrenal gland.strongdo offer extended lymph node dissection patients organ-confined disease.weakoffer embolisation patients unfit surgery presenting massive haematuria flank pain.weak